| | Donors | Recipients |
|---|
| Age (years) | 55 ± 11 | 46 ± 16 |
| Sex ratio; male:female | 16:29 | 25:20 |
| Height (cm) | 159 ± 8 | 163 ± 9 |
| Body weight (kg) | 57 ± 12 | 56 ± 12 |
| Body mass index (kg/m2) | 22.5 ± 3.6 | 21.0 ± 3.8 |
| Complications |
| Hypertension | 7 (16%) | 31 (67%) |
| Hyperlipidemia | 6 (13%) | 23 (51%) |
| Diabetes | 0 (0%) | 14 (31%) |
| Blood relatives | 27 (60%) | |
| Dialysis vintage (months)a | | 23 (2–82) |
| Preemptive kidney transplantation | | 11 (24%) |
| Causes of renal failure |
| Chronic glomerulonephritis | | 24 (53%) |
| Diabetic nephropathy | | 4 (9%) |
| CAKUT | | 3 (7%) |
| ANCA associated vasculitis | | 3 (7%) |
| ADPKD | | 3 (7%) |
| Lupus nephritis | | 2 (4%) |
| Others and unknown | | 6 (13%) |
| Immunosuppressant |
| Mycophenolate mofetil | | 42 (93%) |
| Mizolibin | | 2 (4%) |
| Everolimus | | 22 (49%) |
| Tacrolimus | | 42 (93%) |
| Cyclosporin | | 3 (7%) |
| mPSL | | 45 (100%) |
- CAKUT, congenital anomalies of the kidney and urinary tract; ANCA, anti-neutrophil cytoplasmic antibody; ADPKD, autosomal dominant polycystic kidney disease; MMF, mycophenolate mofetil; mPSL, methylprednisolone
- aMedian (interquartile range)
